<SEC-DOCUMENT>0001171843-25-005877.txt : 20250912
<SEC-HEADER>0001171843-25-005877.hdr.sgml : 20250912
<ACCEPTANCE-DATETIME>20250912075006
ACCESSION NUMBER:		0001171843-25-005877
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250912
FILED AS OF DATE:		20250912
DATE AS OF CHANGE:		20250912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Quantum Biopharma Ltd.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		251310060

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		55 UNIVERSITY AVENUE, SUITE 1003
		CITY:			TORONTO
		PROVINCE COUNTRY:   	A6
		ZIP:			M5J 2H7
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		55 UNIVERSITY AVENUE, SUITE 1003
		CITY:			TORONTO
		PROVINCE COUNTRY:   	A6
		ZIP:			M5J 2H7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FSD Pharma Inc.
		DATE OF NAME CHANGE:	20190327
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_091125.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of September 2025</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39152</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Quantum BioPharma Ltd.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>55 University Ave., Suite 1003<br />Toronto, Ontario M5J2H7, Canada</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><p>&#160;</p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p><hr style="page-break-after: always;" noshade="noshade" /><p> On September 12, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br />(c) Exhibit 99.1. Press release dated September 12, 2025</p><p></p>--><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Quantum BioPharma Ltd.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: September 12, 2025</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Donal Carroll&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Donal Carroll</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Financial Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table><p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><p style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit Number</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td><font style="font-size: 10pt;"></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">Press Release dated September 12, 2025</a> </font></td></tr></table></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT</strong></font></p><p style="text-align: center;"><strong></strong></p><p ></p>
   <p align="justify">TORONTO, Sept.  12, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (&#8220;<strong>Quantum BioPharma</strong>&#8221; or the &#8220;<strong>Company</strong>&#8221;), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee &#8211; Unbuzzd Wellness Inc. (the "<strong>Company</strong>" or "<strong>Unbuzzd</strong>"), the company behind unbuzzd<sup>TM</sup> &#8212; the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, will host an Investor Webinar on Tuesday, September 16, 2025 at 1:30 p.m. Pacific time, 4:30 p.m. Eastern Standard Time.</p>    <p align="justify">During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will discuss the current Reg D 506(c) investment opportunity for its scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about Unbuzzd Wellness&#8217; strategies to accelerate direct-to-consumer, distributor, and retail sales. A question-and-answer session will follow the presentation. To register, please click here link.</p>    <p align="justify">CEO John Duffy commented, &#8220;We look forward to this opportunity to engage and inform current and potential investors about the rapidly expanding global market for unbuzzd. We will review the science behind how it works, and discuss results from our double-blind, placebo-controlled clinical study. We will also discuss the current opportunity to invest in our Regulation D 506(c) offering where we expect to raise up to US$5.0 million to support our aggressive expansion plans, and possible initial public offering.&#8221;</p>    <p align="justify">Quantum BioPharma shareholders will not be diluted by this offering.</p>    <p align="justify">A replay of the webinar will be available upon request by contacting investor@unbuzzd.com or by calling 518-862-5993. To learn more about the Reg D 506(c) offering or begin your investment, please visit us at invest.unbuzzd.com</p>    <p align="justify"><strong>About Unbuzzd Wellness Inc.</strong></p>    <p align="justify">Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&amp;D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.</p>    <p align="justify">Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("<strong>BAC</strong>"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:</p>    <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>Accelerated Alcohol Metabolism</u></strong>: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects.</li><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>Rapid Improvements in Alertness</u></strong>: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.</li><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>Rapid Improvements in Physiologic Changes due to Intoxication</u></strong>: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.</li><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>Reduced Perceived Impairment and Mental Fatigue</u></strong>: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.</li><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>Hangover Relief</u></strong>: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.</li><li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;"><strong><u>No Side Effects</u></strong>: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.</li></ul>    <p align="justify">The full press release of the clinical trial can be found here.</p>    <p align="justify">unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com.</p>    <p align="justify">Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.</p>    <p align="center">    <img src="image_001.jpg" alt=""><p align="center"><strong>8</strong>-<strong>pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks</strong></p>    <p align="center">To view an enhanced version of this graphic, please visit: link</p>    <p align="left"><strong>About Quantum BioPharma Ltd.</strong></p>    <p align="justify">Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (&#8220;Lucid&#8221;), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd&#153; and spun out its OTC version to a company, Celly Nutrition Corp. (&#8220;Celly Nutrition&#8221;), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd&#153; until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.</p>    <p align="justify">For more information visit www.quantumbiopharma.com.</p>    <p align="justify"><strong>Forward-Looking Information</strong></p>    <p align="justify"><em>This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma&#8217;s filings on SEDAR+ (</em><em>www.sedarplus.ca</em><em>) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.</em></p>    <p align="justify"><em>The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission&#8217;s website at </em><em>www.sec.gov</em><em> for a more complete discussion of such risk factors and their potential effects.</em></p>    <p align="justify"><strong>Contacts:</strong></p>    <p align="left"><strong>Quantum BioPharma Ltd.</strong> <br >Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board <br >Email: Zsaeed@quantumbiopharma.com&#160;&#160; <br >Telephone: (833) 571-1811</p>    <p align="left"><strong>Unbuzzd Wellness, Inc.</strong><br >John Duffy, Chief Executive Officer<br >Email: johnduffy@unbuzzd.com&#160;<br >Telephone: (508) 479-4923</p>    <p align="left"><strong>Investor Relations </strong><br >Investor Relations: IR@QuantumBioPharma.com <br >General Inquiries: info@QuantumBioPharma.com &#160;&#160;&#160;</p>    <p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/051d9e95-6ad2-4818-b814-f43e0c8ddd5f</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "B B8# 2(  A$! Q$!_\0
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MMJ\89<AN_I2;#8N8I*ABNHIO]7(I]N]3=:- 30ZBBBF 4444 %%%% !1110
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M#XVE5JNE%ZHY(QG&2?0[^BBBO3.X**** "BBB@ HHHH **** "BBB@ HHHH
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MYX S^%7S'H>VEV/:+OQ-I-FL1DO8RLN=C)\XX^E/A\0Z5<_ZJ^A=L?=W8)_
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MY,_DM*6B./&?P6<Q\,AJ#RZD+>"VDM_DRUQ]U'_+/3^E2>/I-7$UK!?I:);
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M)F*Y]>237-2?-/G6S.:<6DDSI_B!#Y T:+=G;:;<^O2GV-_/#X$_?Q6=U81
MKY<L\V[>6X&P?+QG(/\ 6CXC<W^FCTMOZBJTID'@:+]WJ#0L-OF+>9MU8/G:
MT0'!QSSUZT\0DW$J3M.7H;GPIP=<_P"W9O\ T(5[N*\&^$W_ "'S_P!<'_\
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M_0:V*R/#'_(LZ;_U[1_^@BM>NSH?44O@0M%%%!J%%%% !1110 4444 %%%%
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MM/T?6A'&T>DWA..C6[''YBM0>'O$]PNS^RY54C'W$3BO;?PI:KV<>I"RZ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
